Actively Recruiting
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Led by Conjupro Biotherapeutics, Inc. · Updated on 2026-01-21
270
Participants Needed
3
Research Sites
195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
CONDITIONS
Official Title
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors
- Unresponsive or intolerant to all standard of care or no standard of care available
- At least one measurable tumor lesion according to RECIST v1.1
- ECOG performance status score of 2 or less
- Expected survival of at least 3 months
You will not qualify if you...
- Active central nervous system metastases or leptomeningeal metastases
- Adverse events from prior therapies not recovered to Grade 1 or baseline per NCI CTCAE v5.0
- Use of other unapproved investigational drugs or treatments within 4 weeks before first dose
- Chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor therapies within 4 weeks before first dose, except:
- Nitrosoureas or mitomycin C within 6 weeks before first dose
- Oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives before first dose
- Herbal medicines/products with anti-tumor indications within 2 weeks before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Carolina BioOncology Institute
Huntersville, North Carolina, United States, 28078
Actively Recruiting
2
NEXT Dallas
Dallas, Texas, United States, 75039
Actively Recruiting
3
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
K
Kevin Romanko
CONTACT
A
Audrey Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here